CTLA4 and melanoma: The first MAb to receive approval by the US FDA for clinical application in the setting of selected, advanced malignancies was the CTLA-4-targeted agent, ipilimumab, a fully human IgG1 MAb, approved initially for treatment of advanced melanoma in 2011 (23, 24).